News stories about Impax Laboratories (NASDAQ:IPXL) have been trending somewhat positive this week, Accern reports. Accern scores the sentiment of news coverage by reviewing more than 20 million blog and news sources in real time. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Impax Laboratories earned a news impact score of 0.20 on Accern’s scale. Accern also gave media headlines about the specialty pharmaceutical company an impact score of 44.9883842085103 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the next few days.

Here are some of the media headlines that may have impacted Accern Sentiment Analysis’s rankings:

A number of equities research analysts have recently weighed in on IPXL shares. Cantor Fitzgerald boosted their price target on Impax Laboratories from $20.00 to $25.00 and gave the company an “overweight” rating in a report on Monday, September 11th. Zacks Investment Research upgraded Impax Laboratories from a “hold” rating to a “buy” rating and set a $19.00 price target for the company in a report on Tuesday, July 11th. BMO Capital Markets reiterated a “hold” rating and issued a $16.00 price target on shares of Impax Laboratories in a report on Friday, June 23rd. Citigroup Inc. boosted their price target on Impax Laboratories to $23.00 and gave the company a “buy” rating in a report on Tuesday, September 19th. Finally, Deutsche Bank AG reiterated a “buy” rating and issued a $23.00 price target on shares of Impax Laboratories in a report on Tuesday, September 19th. Four analysts have rated the stock with a sell rating, eleven have given a hold rating and five have given a buy rating to the company’s stock. The stock currently has an average rating of “Hold” and a consensus price target of $18.70.

Impax Laboratories (NASDAQ:IPXL) traded down 0.816% on Thursday, reaching $21.275. The company had a trading volume of 745,994 shares. The stock’s market cap is $1.53 billion. Impax Laboratories has a one year low of $7.75 and a one year high of $25.70. The company has a 50-day moving average of $20.67 and a 200 day moving average of $16.61.

Impax Laboratories (NASDAQ:IPXL) last issued its earnings results on Wednesday, August 9th. The specialty pharmaceutical company reported $0.18 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.14 by $0.04. Impax Laboratories had a positive return on equity of 9.05% and a negative net margin of 71.08%. The business had revenue of $202.08 million during the quarter, compared to analysts’ expectations of $195.62 million. During the same period in the prior year, the firm posted $0.21 EPS. Impax Laboratories’s quarterly revenue was up 17.1% compared to the same quarter last year. On average, equities research analysts predict that Impax Laboratories will post $0.70 EPS for the current year.

TRADEMARK VIOLATION NOTICE: “Somewhat Positive Media Coverage Somewhat Unlikely to Affect Impax Laboratories (IPXL) Share Price” was first reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are accessing this piece on another site, it was stolen and republished in violation of U.S. & international trademark and copyright law. The legal version of this piece can be viewed at https://www.thecerbatgem.com/2017/10/05/somewhat-positive-media-coverage-somewhat-unlikely-to-affect-impax-laboratories-ipxl-share-price.html.

About Impax Laboratories

Impax Laboratories, Inc is a specialty pharmaceutical company. The Company is engaged in the development, manufacture and marketing of bioequivalent pharmaceutical products (generics), in addition to the development and marketing of branded products. Its segments include Impax Generics and Impax Specialty Pharma.

Insider Buying and Selling by Quarter for Impax Laboratories (NASDAQ:IPXL)

Receive News & Stock Ratings for Impax Laboratories Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Impax Laboratories Inc. and related stocks with our FREE daily email newsletter.